Insider trade

Jasper Therapeutics (JSPR): Director received 7,500 units

Thomas G Wiggans, Director at Jasper Therapeutics, reported a grant / award of 7,500 units.

7,500
Derivative units
Traded
Jul 31, 2026
Filed
Aug 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 3, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On June 3, 2026, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule…”
  2. Jul 16, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and changed a top executive or board member (and 4 more items)“Resignation of Directors In accordance with the Merger Agreement, on July 16, 2026, Vishal Kapoor and Scott Brun, M.D., notified the Board of their resignations, each effective immediately after the Effective Time.”

What came next

  1. Aug 14, 2026Company filing · Form 8-K · ResultsReported its results
  2. Aug 21, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  3. Sep 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the “ Company ”) in order to pursue other professional endeavors.”
  4. Oct 28, 20265% stakeBANK OF AMERICA CORP /DE/ reported a passive stake (13G) of 6.4%
  5. Nov 2, 2026Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year (and 1 more item)
  6. Nov 13, 20265% stakeAffinity Asset Advisors, LLC reported a passive stake (13G) of 5.6%
  7. Nov 16, 2026Company filing · Form 8-K · ResultsReported its results
  8. Nov 16, 20265% stakeArmistice Capital, LLC reported a passive stake (13G) of 10.0%
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Jasper Therapeutics

For Jasper Therapeutics, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JSPR page.

Other recent filings by Thomas G Wiggans, Director

The full history of Thomas G Wiggans, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Jasper Therapeutics (JSPR) insider traded, and how much?

Thomas G Wiggans, Director at Jasper Therapeutics, reported a grant / award of 7,500 units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Jul 31, 2026. Filed: Aug 5, 2026. That is 5 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Jasper Therapeutics recently?

For Jasper Therapeutics, OQRO holds 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the JSPR page.

Does this mean JSPR stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Jasper Therapeutics

Everything OQRO holds on this company is on its JSPR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data